Use of intravenous immunoglobulin in critically ill patients.
Intravenous immunoglobulin (IVIG) has been suggested for the treatment of many ailments due to its ability to modulate the immune system and to provide passive immunity to commonly circulating pathogens. Its use as primary and adjunctive therapy for the treatment of conditions affecting critically ill patients is an attractive option, especially when alternative therapy does not exist. The body of literature on the use of IVIG for the treatment of several serious conditions, including sepsis, toxic shock syndrome, acute myocarditis, Stevens-Johnson syndrome, toxic epidermal necrolysis, and H1N1 influenza, were reviewed. Despite advances in treatment of these conditions since they were first described, there remains a paucity of well-designed studies on the use of IVIG for their treatment. Therefore, the use of IVIG for treatment of these conditions remains controversial.
Pediatric Infectious Diseases Fellow, Virginia Commonwealth University Health System, VCU Sanger Hall 12-041, P.O. Box 980163, Richmond, VA, 23298-0163, USA, sdonovan@mcvh-vcu.edu.
Summer
S
Donovan
Gonzalo M L
GM
Bearman